Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

Not intended for UK-based media Collaboration complements Merck KGaA, Darmstadt, Germany's internal expertise and in-house ADC approach Companies focused on discovering novel STING-agonist

Related Keywords

Germany ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Massachusetts ,Paul Lyne ,Anna Protopapas ,Head Of Research Unit Oncology ,Merck Kga ,Merck Kgaa ,Serono ,Mersana Therapeutics Inc ,United Kingdom Based ,Mersana Therapeutics ,Research Unit Oncology ,Chief Executive Officer ,Merck ,Gaa ,Armstadt ,Nnounces ,Collaboration ,Eversana ,Herapeutics ,Evelop ,Novel ,Mmunostimulatory ,Ntibody ,Drug ,Conjugates ,